To lower this possibility, we suggest that using neoadjuvant therapy (NAT) that ‘bypasses’ the androgen receptor may be more beneficial to PCa patients, since it may enable tumors to retain sensitivity to subsequent AR targeting (for example in the case of recurrence after prostatectomy). Here, AR is linked to posterior cortical atrophy.